Anaptysbio Inc (ANAB)

Dec 10, 2025

J.P. Morgan Maintains a Sell Rating on GSK plc (GSK) - Finviz

Dec 10, 2025

Dec 10, 2025

JP Morgan maintains a sell rating on GSK plc (GSK) - MSN

Dec 10, 2025

Dec 09, 2025

AnaptysBio (NASDAQ:ANAB) Hits New 1-Year HighStill a Buy? - MarketBeat

Dec 09, 2025

Dec 07, 2025

Discipline and Rules-Based Execution in ANAB Response - news.stocktradersdaily.com

Dec 07, 2025

Dec 06, 2025

33,369 Shares in AnaptysBio, Inc. $ANAB Acquired by Panagora Asset Management Inc. - MarketBeat

Dec 06, 2025

Dec 06, 2025

AnaptysBio Files Legal Complaint Against GSK and Tesaro - MSN

Dec 06, 2025

Dec 04, 2025

AnaptysBio (NASDAQ:ANAB) Reaches New 1-Year HighHere's Why - MarketBeat

Dec 04, 2025

Dec 04, 2025

30,642 Shares in AnaptysBio, Inc. $ANAB Bought by XTX Topco Ltd - MarketBeat

Dec 04, 2025

Dec 04, 2025

Geode Capital Management LLC Sells 27,809 Shares of AnaptysBio, Inc. $ANAB - MarketBeat

Dec 04, 2025

Dec 04, 2025

Will AnaptysBio Inc. stock deliver consistent dividendsWeekly Stock Report & Daily Volume Surge Trade Alerts - Newser

Dec 04, 2025

Dec 03, 2025

AnaptysBio stock hits 52-week high at 43.35 USD - Investing.com

Dec 03, 2025

Dec 03, 2025

AnaptysBio stock hits 52-week high at 43.35 USD By Investing.com - Investing.com Nigeria

Dec 03, 2025

Dec 03, 2025

AnaptysBio Shares Navigate Legal Headwinds Amid Strong Performance - AD HOC NEWS

Dec 03, 2025

Dec 03, 2025

How institutional buying supports AnaptysBio Inc. stockMarket Performance Recap & Smart Money Movement Alerts - Newser

Dec 03, 2025

Dec 03, 2025

Why AnaptysBio Inc. (AN6) stock could break out in 2025Market Activity Recap & Real-Time Market Trend Scan - Newser

Dec 03, 2025

Dec 02, 2025

The Bull Case For AnaptysBio (ANAB) Could Change Following Jemperli Legal Clash With GSK Subsidiary - Yahoo Finance

Dec 02, 2025

Dec 02, 2025

Virtus Investment Advisers LLC Sells 6,909 Shares of AnaptysBio, Inc. $ANAB - MarketBeat

Dec 02, 2025

Dec 02, 2025

Jemperli Royalty Dispute Could Be a Game Changer for AnaptysBio (ANAB) - Sahm

Dec 02, 2025

Dec 02, 2025

Is AnaptysBio Inc. (AN6) stock a top hedge fund pickQuarterly Growth Report & Real-Time Market Sentiment Reports - Newser

Dec 02, 2025

Dec 02, 2025

What sentiment indicators say about AnaptysBio Inc. stockPortfolio Return Report & Entry and Exit Point Strategies - Newser

Dec 02, 2025

Dec 01, 2025

ANAB: AnaptyBio Among Top Quality Stocks with High Returns - GuruFocus

Dec 01, 2025

Nov 28, 2025

AnaptysBio, GSK's Tesaro Unit Likely Settle Jemperli Dispute Before July, Wedbush Says - marketscreener.com

Nov 28, 2025

Nov 28, 2025

A Look at AnaptysBio's Valuation as Litigation With GSK Over Jemperli Royalties Draws Investor Focus - simplywall.st

Nov 28, 2025

Nov 27, 2025

AnaptysBio Reports Q3 2025 Results and Strategic Plans - MSN

Nov 27, 2025

Nov 27, 2025

Why AnaptysBio Inc. stock could rally in 2025Portfolio Update Report & AI Powered Buy and Sell Recommendations - BỘ NỘI VỤ

Nov 27, 2025

Nov 27, 2025

AnaptysBio FY2025 EPS Estimate Boosted by HC Wainwright - MarketBeat

Nov 27, 2025

Nov 27, 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Nov 27, 2025

Nov 26, 2025

AnaptysBio's complaint against Tesaro for breaching agreement was publicly filed on Nov 26SEC filing - marketscreener.com

Nov 26, 2025

Nov 26, 2025

AnaptysBio files lawsuit against Tesaro and GSK over license deal - StreetInsider

Nov 26, 2025

Nov 26, 2025

AnaptysBio, Inc Files Lawsuit Against Tesaro and GSK - TradingView

Nov 26, 2025

Nov 26, 2025

Behavioral Patterns of ANAB and Institutional Flows - news.stocktradersdaily.com

Nov 26, 2025

Nov 25, 2025

What drives AnaptysBio Inc AN6 stock priceEconomic Data Impact & Rapid Portfolio Appreciation - earlytimes.in

Nov 25, 2025

Nov 25, 2025

Anaptys Announces Participation in December Investor Conferences - The Manila Times

Nov 25, 2025

Nov 25, 2025

AnaptysBio, Inc. to Participate in Upcoming Investor Conferences Featuring Leadership Team Insights - Quiver Quantitative

Nov 25, 2025

Nov 25, 2025

Wedbush Backs AnaptysBio As Buyback Eases Investor Fears - Finimize

Nov 25, 2025

Nov 25, 2025

AnaptysBio (NASDAQ:ANAB) Sets New 52-Week HighHere's What Happened - MarketBeat

Nov 25, 2025

Nov 25, 2025

AnaptysBio's (ANAB) Outperform Rating Reiterated at Wedbush - MarketBeat

Nov 25, 2025

Nov 25, 2025

HC Wainwright Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat

Nov 25, 2025

Nov 25, 2025

DCF Advisers LLC Purchases 13,150 Shares of AnaptysBio, Inc. $ANAB - MarketBeat

Nov 25, 2025

Nov 24, 2025

HC Wainwright & Co. Maintains AnaptysBio (ANAB) Buy Recommendation - Nasdaq

Nov 24, 2025

Nov 24, 2025

AnaptysBio stock hits 52-week high at 41.12 USD By Investing.com - Investing.com Nigeria

Nov 24, 2025

Nov 24, 2025

AnaptysBio stock hits 52-week high at 41.12 USD - Investing.com

Nov 24, 2025

Nov 24, 2025

GSK's TESARO sues AnaptysBio over alleged breach of cancer drug licence deal - Indian Pharma Post

Nov 24, 2025

Nov 24, 2025

ANAB: Wedbush Reiterates Outperform Rating and $50 Price Target - GuruFocus

Nov 24, 2025

Nov 24, 2025

Anaptys Announces $100 Million Stock Repurchase Plan - MarketScreener

Nov 24, 2025

Nov 24, 2025

AnaptysBio Presents Opportunity Despite 'Near-Term Turbulence' Amid Legal Dispute with GSK, Wedbush Says - marketscreener.com

Nov 24, 2025

Nov 24, 2025

AnaptysBio (ANAB) Analyst Rating Update: PT Lowered by HC Wainwr - GuruFocus

Nov 24, 2025

Nov 23, 2025

Is AnaptysBio Inc AN6 a good long term investmentShort Selling Opportunities & Double Or Triple Investment - earlytimes.in

Nov 23, 2025

Nov 23, 2025

ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal - MSN

Nov 23, 2025

Nov 22, 2025

Share Buyback Program Declared by AnaptysBio (NASDAQ:ANAB) Board of Directors - MarketBeat

Nov 22, 2025

Nov 22, 2025

AnaptysBio Inc Stock Analysis and ForecastDebt-to-Equity Ratio Analysis & Double Or Triple Capital - earlytimes.in

Nov 22, 2025